Sonnet Biotherapeutics Holdings Inc reports results for the quarter ended in March - Earnings Summary
15/05/2024 15:21
* Sonnet Biotherapeutics Holdings Inc SONN.OQ reported
quarterly
adjusted earnings of 7 cents per share for the quarter ended
in March, higher than the same quarter last year, when the
company reported EPS of $-7.48. The mean expectation of
two analysts for the quarter was for earnings of 14 cents per
share. Wall Street expected results to range from -30 cents
to 57 cents per share.
* Reported revenue was zero; analysts expected $12.33
thousand.
* Sonnet Biotherapeutics Holdings Inc's reported EPS for the
quarter was 7 cents.
* The company reported quarterly net income of $365.43
thousand.
* Sonnet Biotherapeutics Holdings Inc shares had fallen
by 2.7%
this quarter and gained 4.0% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had risen by
about 196.4%
in the last three months.
* In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 4 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."
* The average consensus recommendation for the
pharmaceuticals
peer group is "buy."
Wall Street's median 12-month price target for Sonnet
Biotherapeutics Holdings Inc is $20.50
This summary was machine generated from LSEG data May 15 at
02:21 p.m. UTC. All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Mar. 31 2024 0.14 0.07 Missed
Dec. 31 2023 -0.90 -0.31 Beat
Sep. 30 2023 -4.09 -2.09 Beat
Jun. 30 2023 -6.82 -2.86 Beat